George Golumbeski

Earlier this year, Golumbeski left his job at pharmaceutical giant Novartis, where he had been vice president of business development, to take the reins of the Austrian biotech company Nabrivia Therapeutics. As chief executive officer, he oversees a 55-person team working on the next generation of antibiotics—including three developmental products designed to fight methicillin-resistant staphylococcus aureus, a frightening bacterial infection that doesn’t respond to common antibiotics. Golumbeski enjoys tackling the scientific, organizational and fiscal issues in bringing new drugs to patients. “After nearly 20 years,” he says, “my work remains fresh, complex and very challenging.”